The Zhitong Finance App learned that UBS released a research report stating that it will maintain Tiger Pharmaceuticals (03347.HK)'s “buy” rating and target price of HK$52.6. Tiger Pharmaceuticals announced that it will participate in the privatization and business spin-off of Fangda Holdings (01521.HK) through its wholly-owned subsidiary Hong Kong Tiger. UBS believes that if the transaction is completed according to the plan, Tiger Pharmaceuticals may be able to obtain non-target business in mainland China and approximately RMB 1.81 billion in cash, and has the right to receive additional consideration payments from Charles River Laboratories. The transaction may help Tiger Pharmaceuticals divest non-core businesses and focus on clinical CRO services.
Zhitongcaijing · 2d ago
Share
Listen to the news
The Zhitong Finance App learned that UBS released a research report stating that it will maintain Tiger Pharmaceuticals (03347.HK)'s “buy” rating and target price of HK$52.6. Tiger Pharmaceuticals announced that it will participate in the privatization and business spin-off of Fangda Holdings (01521.HK) through its wholly-owned subsidiary Hong Kong Tiger. UBS believes that if the transaction is completed according to the plan, Tiger Pharmaceuticals may be able to obtain non-target business in mainland China and approximately RMB 1.81 billion in cash, and has the right to receive additional consideration payments from Charles River Laboratories. The transaction may help Tiger Pharmaceuticals divest non-core businesses and focus on clinical CRO services.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending